GlassScriptPhysician profile
Debra Wilder
NPI 1174513915
$4,863.80
in general payments reported to CMS, 2019-2025
35 companies · $706 in 2025
The $706 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $774 · 2021: $973 · 2022: $719 · 2023: $524 · 2024: $686 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,073.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $487.27 | 2020-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $348.38 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $339.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $323.56 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $310.79 | 2019-2025 | |
| Lilly USA, LLC | $263.82 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $222.72 | 2020-2025 | |
| Amarin Pharma, INC. | $157.10 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.69 | 2023-2025 | |
| Exact Sciences Corporation | $145.77 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.68 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $117.23 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $110.19 | 2019-2023 | Eliquis |
| Allergan, INC. | $87.06 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.48 | 2020-2021 | |
| Dexcom, INC. | $60.11 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $58.78 | 2023-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $40.90 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $40.20 | 2025 | Voquezna |
| Eisai INC. | $37.51 | 2021 | |
| Sunovion Pharmaceuticals INC. | $36.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.76 | 2023 | Rexulti |
| Boston Scientific Corporation | $20.74 | 2022 | |
| Grifols USA, LLC | $20.65 | 2020 | |
| Abbott Laboratories | $20.10 | 2025 | Eterna |
| Alkermes, INC. | $19.54 | 2022 | |
| Neurocrine Biosciences, INC. | $19.51 | 2024 | Ingrezza |
| Mylan Specialty L.P. | $17.41 | 2024 | Yupelri |
| Almatica Pharma LLC | $16.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2021 | |
| Merck Sharp & Dohme LLC | $15.94 | 2024 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $15.05 | 2019 | |
| Astellas Pharma US INC | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.